Status:
TERMINATED
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and effective as 4 weekl...
Eligibility Criteria
Inclusion
- adult patients, 18-80 years of age;
- stage 3-4 chronic kidney disease (eGFR 15-60mL/min);
- Hb \<100g/L, TSAT\>=20%, and ferritin \>=100 mcg/L at screening.
Exclusion
- anticipating to go on renal replacement therapy;
- anticipating a living related-donor kidney transplant, or a prior recipient of a kidney transplant;
- uncontrolled hypertension;
- congestive heart failure;
- active bleeding or red blood cell transfusions in 8 weeks prior to screening; systematic hematological disease.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00440063
Last Update
December 20 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide, Australia
2
Gosford, Australia
3
Herston, Australia
4
Liverpool, Australia